Bone Growth Stimulators Market Size, Share and Geography Forecast till 2026

Posted by Rushikesh Pise on December 3rd, 2019

Recent innovations and clinical approvals are supporting growth in Global Bone Growth Stimulators Market. With clear pathways for future growth.

In April 2019, a team of analysts at the University of Michigan introduced a theory that High Intensity Focused Ultrasound (HIFU) and gene switches can be of a massive help in stimulating the growth of bones. The HIFU is already clinically approved by the FDA and has shown positive clinical results. This method is set to change the way bone growth stimulators have been operating. When used simultaneously, HIFU and gene switches can speed up growth stimulation processes, thereby taking lesser time for tissue regeneration and healing. Discovery of such methods have led to an increased adoption of bone growth stimulators, worldwide.

Browse Complete Report Details:

  •          Zimmer Biomet
  •          Stryker
  •          Medtronic
  •          Wright Medical Group N.V.
  •          Orthofix Holdings, Inc.
  •          Prospec-Tany Technogene Ltd
  •          Elizur Corporation
  •          Bioventus Ossatec
  •          Benelux BV
  •          IGEA S.p.a

The Global Bone Growth Stimulators Market is likely to gain traction from recent advancements in tissue regeneration and healing. According to a report by Fortune Business Insights, titled “Bone Growth Stimulators Market Size, Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Non-union and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026,” the market was valued at  US$ 1,837.2 Mn in 2018. Fortune Business Insights further states that this market will be valued at US$ 2,624.8 Mn by the end of 2026, thereby exhibiting a CAGR of 4.6%.

Long Awaited FDA Approval for Orthfix’s PhysioStim Has Encouraged Market Competitors

In 2018, Orthofix announced that it has received FDA and CE mark approvals for its PhysioStim bone growth stimulators. PhysioStim offered tissue regeneration and recombining without the need to undergo surgical procedures. The FDA approval for PhysioStim and other such products have encouraged other market players to come up with their own products and improve existing methods. Such drug approvals have a positive impact on the global bone growth stimulators market and is likely to favour growth of this market in the forecast period.

Conventional bone growth stimulators were mostly manufactured using patented drugs. Most of the stimulators were manufactured with the help of very few drug options. But in recent years, newer drugs have been approved for manufacturing and study of bone growth stimulators.


Like it? Share it!

Rushikesh Pise

About the Author

Rushikesh Pise
Joined: November 4th, 2019
Articles Posted: 81

More by this author